JP2023502182A5 - - Google Patents
Info
- Publication number
- JP2023502182A5 JP2023502182A5 JP2022554171A JP2022554171A JP2023502182A5 JP 2023502182 A5 JP2023502182 A5 JP 2023502182A5 JP 2022554171 A JP2022554171 A JP 2022554171A JP 2022554171 A JP2022554171 A JP 2022554171A JP 2023502182 A5 JP2023502182 A5 JP 2023502182A5
- Authority
- JP
- Japan
- Prior art keywords
- ido
- prodrug
- liposome
- liposome according
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025052649A JP2025092573A (ja) | 2019-11-12 | 2025-03-26 | がんの処置において有用なｉｄｏアンタゴニストプロドラッグを含有する製剤化および／または共製剤化されたリポソーム組成物およびその方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962974086P | 2019-11-12 | 2019-11-12 | |
| US62/974,086 | 2019-11-12 | ||
| PCT/US2020/000044 WO2021096542A1 (en) | 2019-11-12 | 2020-11-12 | Formulated and/or co-formulated liposome compositions containing ido antagonist prodrugs useful in the treatment of cancer and methods thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025052649A Division JP2025092573A (ja) | 2019-11-12 | 2025-03-26 | がんの処置において有用なｉｄｏアンタゴニストプロドラッグを含有する製剤化および／または共製剤化されたリポソーム組成物およびその方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023502182A JP2023502182A (ja) | 2023-01-20 |
| JP2023502182A5 true JP2023502182A5 (https=) | 2023-11-20 |
Family
ID=73835687
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554171A Pending JP2023502182A (ja) | 2019-11-12 | 2020-11-12 | がんの処置において有用なｉｄｏアンタゴニストプロドラッグを含有する製剤化および／または共製剤化されたリポソーム組成物およびその方法 |
| JP2025052649A Pending JP2025092573A (ja) | 2019-11-12 | 2025-03-26 | がんの処置において有用なｉｄｏアンタゴニストプロドラッグを含有する製剤化および／または共製剤化されたリポソーム組成物およびその方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025052649A Pending JP2025092573A (ja) | 2019-11-12 | 2025-03-26 | がんの処置において有用なｉｄｏアンタゴニストプロドラッグを含有する製剤化および／または共製剤化されたリポソーム組成物およびその方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12286403B2 (https=) |
| EP (1) | EP4041402A1 (https=) |
| JP (2) | JP2023502182A (https=) |
| KR (1) | KR20220100904A (https=) |
| CN (2) | CN118286450A (https=) |
| AU (2) | AU2020384481B2 (https=) |
| CA (1) | CA3159783A1 (https=) |
| WO (1) | WO2021096542A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3211133A1 (en) * | 2021-03-18 | 2022-09-22 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing a2ar antagonist prodrugs useful in the treatment of cancer and methods thereof |
| JPWO2025121339A1 (https=) * | 2023-12-04 | 2025-06-12 | ||
| CN119792580A (zh) * | 2025-01-02 | 2025-04-11 | 浙江大学 | ID3 mRNA脂质纳米颗粒制备方法及在眼角膜疾病治疗中的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
| WO2006005185A1 (en) | 2004-07-13 | 2006-01-19 | The University Of British Columbia | Indoleamine 2,3-dioxygenase (ido) inhibitors |
| US8389568B2 (en) | 2007-03-16 | 2013-03-05 | Lankenau Institute For Medical Research | IDO inhibitors and methods of use thereof |
| CA2722159C (en) | 2008-04-24 | 2016-04-05 | Newlink Genetics Corporation | Substituted phenylimidazole compounds and their use as ido inhibitors |
| JP5465720B2 (ja) | 2008-07-08 | 2014-04-09 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール |
| PT104158B (pt) | 2008-08-18 | 2011-02-24 | Univ Do Minho | Aplicação da monooleína como novo lípido adjuvante em lipofecção |
| US8934953B2 (en) | 2011-05-04 | 2015-01-13 | Meridian Medical Systems, Llc | Dual mode temperature transducer with oxygen saturation sensor |
| JP6076968B2 (ja) | 2011-06-06 | 2017-02-08 | ユニバーシティ・ヘルス・ネットワーク | ポルフィリン−リン脂質コンジュゲートを合成する方法 |
| CA2889182A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| KR20150087400A (ko) | 2012-11-20 | 2015-07-29 | 버텍스 파마슈티칼스 인코포레이티드 | 인돌아민 2,3-디옥시게나제의 억제제로서 유용한 화합물 |
| EP2970114B1 (en) | 2013-03-15 | 2019-05-15 | Bristol-Myers Squibb Company | Ido inhibitors |
| SG11201606428UA (en) | 2014-02-04 | 2016-09-29 | Incyte Corp | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
| CN105777770B (zh) * | 2014-12-26 | 2018-05-25 | 中国人民解放军第二军医大学 | 一种饱和长链脂肪酸修饰的7-乙基-10-羟基喜树碱化合物及其长循环脂质体 |
| BR112018000217A2 (pt) * | 2015-07-15 | 2018-09-04 | Celator Pharmaceuticals Inc | sistemas de distribuição de nanopartículas aperfeiçoados |
| EP4659747A2 (en) | 2015-07-24 | 2025-12-10 | Lumos Pharma, Inc. | Salts and prodrugs of 1-methyl-d-tryptophan |
| US20180214563A1 (en) | 2015-07-31 | 2018-08-02 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Immunostimulatory nanocarrier |
| SG11201802961PA (en) | 2015-10-30 | 2018-05-30 | Calithera Biosciences Inc | Compositions and methods for inhibiting arginase activity |
| WO2017079669A1 (en) | 2015-11-04 | 2017-05-11 | Incyte Corporation | Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor |
| CN107849084B (zh) | 2015-12-03 | 2021-09-14 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为sting调节剂的环状嘌呤二核苷酸 |
| EP3400218A4 (en) | 2016-01-08 | 2019-09-18 | Euclises Pharmaceuticals, Inc. | COMBINATION OF A CHROME CONNECTION AND A SECOND ACTIVE SUBSTANCE |
| US9624185B1 (en) | 2016-01-20 | 2017-04-18 | Yong Xu | Method for preparing IDO inhibitor epacadostat |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| EP3439666A4 (en) * | 2016-05-20 | 2019-12-11 | The University of Chicago | NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF |
| US10138248B2 (en) | 2016-06-24 | 2018-11-27 | Incyte Corporation | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors |
| CN108424434B (zh) * | 2017-02-13 | 2020-07-28 | 四川大学 | 氯喹胆固醇衍生物及其制备方法和用途 |
| CA3063932A1 (en) * | 2017-05-18 | 2018-11-12 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
| US11266640B2 (en) * | 2017-09-20 | 2022-03-08 | Hangzhou Innogate Pharma Co., Ltd. | Polycyclic compound acting as IDO inhibitor and/or IDO-HDAC dual inhibitor |
| CN110025789A (zh) * | 2019-04-01 | 2019-07-19 | 东南大学 | 一种药物磷脂化合物及其药物组合物和应用 |
-
2020
- 2020-11-12 AU AU2020384481A patent/AU2020384481B2/en active Active
- 2020-11-12 EP EP20824711.4A patent/EP4041402A1/en active Pending
- 2020-11-12 JP JP2022554171A patent/JP2023502182A/ja active Pending
- 2020-11-12 US US16/974,199 patent/US12286403B2/en active Active
- 2020-11-12 KR KR1020227019248A patent/KR20220100904A/ko active Pending
- 2020-11-12 CN CN202410504623.6A patent/CN118286450A/zh active Pending
- 2020-11-12 CN CN202080084835.3A patent/CN115135385B/zh active Active
- 2020-11-12 WO PCT/US2020/000044 patent/WO2021096542A1/en not_active Ceased
- 2020-11-12 CA CA3159783A patent/CA3159783A1/en active Pending
-
2024
- 2024-12-04 US US18/968,029 patent/US20250313531A1/en active Pending
-
2025
- 2025-03-26 JP JP2025052649A patent/JP2025092573A/ja active Pending
-
2026
- 2026-03-10 AU AU2026201779A patent/AU2026201779A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023502182A5 (https=) | ||
| TWI271407B (en) | Methods and compositions for treating inflammatory response | |
| GRALLA et al. | Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules | |
| JP2024515650A5 (https=) | ||
| JP5645340B2 (ja) | 活性成分を含有するカチオンリポソームの投与方法 | |
| JP2024040167A5 (https=) | ||
| EP1299085B1 (en) | Improved liposomal camptothecins and uses thereof | |
| CA2645058A1 (en) | Pharmaceutical composition for external use | |
| US6770653B2 (en) | Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin | |
| EP2266626A1 (en) | Composition for external application comprising transcription factor decoy as active ingredient | |
| Plosker | Pegylated liposomal doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma | |
| US11241448B2 (en) | Methods for cancer therapy | |
| JP2023513698A5 (https=) | ||
| JP2010510327A (ja) | エンドキシフェンの方法および組成物 | |
| US20250025489A1 (en) | Methods of vaccination in premalignant settings | |
| Jivan et al. | Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma in vivo | |
| RS51252B (sr) | Upotreba alopurinola za lečenje palmarno-plantarne eritrodizestezije | |
| TWI853940B (zh) | 以組蛋白去乙醯酶抑制劑治療病毒相關癌症之方法 | |
| JP2023531666A (ja) | オキサゾリジノン化合物、オキサゾリジノン化合物を含むリポソーム組成物、およびそれらの使用方法 | |
| JP2023514324A5 (https=) | ||
| CN101437505A (zh) | 去甲二氢愈创木酸衍生物在治疗抗药性癌症、病毒和微生物感染中的用途 | |
| US20250064784A1 (en) | Liposome composition comprising liposomal prodrug of mitomycin c and methods of treatment | |
| US20140135357A1 (en) | Dose regime for camptothecin derivatives | |
| Daponte et al. | Temozolomide and cisplatin in avdanced malignant melanoma | |
| JPH07126164A (ja) | 持効性抗真菌剤 |